Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Depreciation Expense (2020 - 2025)

Vivos Therapeutics has reported Depreciation Expense over the past 6 years, most recently at -$200000.0 for Q4 2025.

  • Quarterly Depreciation Expense fell 300.0% to -$200000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $700000.0 through Dec 2025, up 75.0% year-over-year, with the annual reading at $700000.0 for FY2025, 40.0% up from the prior year.
  • Depreciation Expense was -$200000.0 for Q4 2025 at Vivos Therapeutics, down from $400000.0 in the prior quarter.
  • Over five years, Depreciation Expense peaked at $400000.0 in Q3 2025 and troughed at -$200000.0 in Q4 2025.
  • The 5-year median for Depreciation Expense is $100000.0 (2021), against an average of $149029.8.
  • Year-over-year, Depreciation Expense skyrocketed 800.67% in 2021 and then plummeted 300.0% in 2025.
  • A 5-year view of Depreciation Expense shows it stood at $100000.0 in 2021, then skyrocketed by 200.0% to $300000.0 in 2022, then tumbled by 33.33% to $200000.0 in 2023, then crashed by 50.0% to $100000.0 in 2024, then plummeted by 300.0% to -$200000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Depreciation Expense are -$200000.0 (Q4 2025), $400000.0 (Q3 2025), and $300000.0 (Q2 2025).